

# KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

## Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2)

March 10-14, 2019 • Whistler Conference Centre • Whistler, British Columbia, Canada

Scientific Organizers: Padmanee Sharma, Aviv Regev, Crystal L. Mackall and Kristen Hege

Sponsored by Autolus Therapeutics, BioLegend, Inc., Cell Research, Roche, Incyte Corporation, Surface Oncology, TESARO, Inc. and Takeda Pharmaceutical Company Limited

Abstract & Scholarship Deadline: November 7, 2018 / Abstract Deadline: December 5, 2018 / Discounted Registration Deadline: January 15, 2019

### SUNDAY, MARCH 10

#### Arrival and Registration

### MONDAY, MARCH 11

#### Welcome and Keynote Address

**Catherine Ju-Ying Wu**, Dana-Farber Cancer Institute, USA  
*Driving Anti-Tumor Responses with Neoantigen Vaccines*

#### Response and Resistance Mechanisms to Cancer Immunotherapy

**Padmanee Sharma**, University of Texas MD Anderson Cancer Center, USA  
*From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy*

**Philip D. Greenberg**, University of Washington, USA  
*Resistance Mechanisms to Engineered T Cell Therapies*

**Speaker to be Announced**

**Short Talk(s) Chosen from Abstracts**

#### Technological Advances for Dissecting Immune Responses

**Ton N. Schumacher**, Netherlands Cancer Institute, Netherlands  
*Evaluating Tumor Antigen-Specific T Cell Responses*

**Michael Angelo**, Stanford University, USA  
*Visualization of Tumor-Immune Components*

**Aviv Regev**, Massachusetts Institute of Technology/Broad Institute, USA  
*Comprehending Anti-Tumor Immune Responses through Single-Cell Studies*

**Short Talk Chosen from Abstracts**

#### Poster Session 1

### TUESDAY, MARCH 12

#### Improving Anti-Tumor Immune Responses

**Chris Takimoto**, Forty-Seven, USA  
*Enhancing Antitumor Immunity by Inhibiting CD47 Signaling*

**Elizabeth G. Trehu**, Jounce Therapeutics, USA  
*Lessons Learned from Clinical Trials Targeting ICOS*

**Thomas Gajewski**, University of Chicago, USA  
*Initiating Anti-Tumor Immune Responses with STING Agonist*

**Speaker to be Announced**

*Epigenetics or Metabolism*

**Short Talk(s) Chosen from Abstracts**

#### Engineering T Cells

**Crystal L. Mackall**, Stanford University, USA  
*Next Generation CAR T Cells*

**Kristen Hege**, Celgene, USA  
*Clinical Development of BCMA CAR-T Cells in Myeloma*

**Carl H. June**, University of Pennsylvania, USA  
*CAR T Cell Therapies: Lessons Learned and Next Steps*

**Short Talk Chosen from Abstracts**

#### Poster Session 2

### WEDNESDAY, MARCH 13

#### Immune Checkpoints: Basic Mechanisms and Novel Targets

**James P. Allison**, University of Texas MD Anderson Cancer Center, USA  
*Immune Checkpoint Therapy: Lessons Learned and Next Steps*

**Lisa M. Coussens**, Oregon Health & Science University, USA  
*Evaluating Myeloid Targets to Enhance Anti-Tumor Immune Responses*

**Speaker to be Announced**

*BITE*

**Speaker to be Announced**

*Oncolytic Viral Therapies*

**Short Talk(s) Chosen from Abstracts**

#### Combinatorial Immunotherapy Strategies

**Sandra Demaria**, Weill Cornell Medical College, USA  
*Combining Immunotherapy with Radiation Therapy*

**Juan C. Jaen**, Arcus Biosciences, USA  
*Targeting Immune Activation via Inhibition of the Adenosine Pathway*

**Antoni Ribas**, University of California, Los Angeles, USA  
*Novel Combination Therapy Strategies*

**Short Talk Chosen from Abstracts**

#### Poster Session 3

### THURSDAY, MARCH 14

#### Progress Report on Immune Monitoring and Clinical Trials

**Robert H. Vonderheide**, University of Pennsylvania School of Medicine, USA  
*Novel Immunotherapy Strategies that Effectively Treat Patients with Pancreatic Cancer*

**Dana Pe'er**, Memorial Sloan Kettering Cancer Center, USA  
*Novel Methods for Evaluating Immune Responses*

**Speaker to be Announced**

*Prostate Cancer or GBM*

**Speaker to be Announced**

*Managing Toxicities*

**Short Talk(s) Chosen from Abstracts**

#### The Future of Cancer Immunotherapy

**Jennifer Ann Wargo**, University of Texas MD Anderson Cancer Center, USA  
*Microbiome Targeting and Future Strategies to Improve Cancer Immunotherapy*

**Michael C. Jensen**, University of Washington School of Medicine/Fred Hutchinson Cancer Research Center, USA  
*From Good to Great: Next Iterative Steps for CAR T Cell Therapy of Childhood Leukemia*

# KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

## Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2)

March 10-14, 2019 • Whistler Conference Centre • Whistler, British Columbia, Canada

Scientific Organizers: Padmanee Sharma, Aviv Regev, Crystal L. Mackall and Kristen Hege

Sponsored by Autolus Therapeutics, BioLegend, Inc., Cell Research, Roche, Incyte Corporation, Surface Oncology, TESARO, Inc. and Takeda Pharmaceutical Company Limited

Abstract & Scholarship Deadline: November 7, 2018 / Abstract Deadline: December 5, 2018 / Discounted Registration Deadline: January 15, 2019

### Speaker to be Announced

*Bispecific Checkpoint Antibodies and T Cell Engagers*

### Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

### FRIDAY, MARCH 15

### Departure